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efei@imm.ac.cn (FAbstract EGb761, a standardized and well-deﬁned product extract of Ginkgo biloba leaves, has
beneﬁcial effects on the treatment of multiple diseases, including diabetes and dyslipidemia.
However, it is still unclear whether EGb761 can increase insulin sensitivity. The objectives of the
present study are to evaluate the effects of EGb761 on insulin sensitivity in an obese and insulin-
resistant mouse model, established through chronic feeding of C57BL/6J mice with a high-fat diet
(HFD), and to explore potential mechanisms. Mice fed with HFD for 18 weeks (starting from
4 weeks of age) developed obesity, dyslipidemia (as indicated by biochemical measurements of
blood glucose, triglyceride (TG), total cholesterol (TC), and free fatty acids (FFA)), and insulin
resistance (as determined by the oral glucose tolerance test (OGTT) and the homeostasis model
assessment of insulin resistance (HOMA-IR) index), compared to control mice fed with a standard
laboratory chow. Oral treatment of the HFD-fed mice with EGb761, at low (100 mg/kg), medium
(200 mg/kg), or high (400 mg/kg) doses, via oral gavage (once daily) for 8 weeks (starting from
26 weeks of age) dose-dependently enhanced glucose tolerance in OGTT, and decreased both
the insulin levels (by 29%, 55%, and 70%, respectively), and the HOMA-IR index values (by 50%,
69%, and 80%, respectively). EGb761 treatment also ameliorated HFD-induced obesity,edica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association. Production and
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EGb761, an extract of Ginkgo biloba leaves, reduces insulin resistance in a high-fat-fed mouse model 15dyslipidemia, and liver injury, as indicated by decreases in body weight (by 4%, 11%, and 16%,
respectively), blood TC levels (by 23%, 32%, and 37%, respectively), blood TG levels (by 17%,
23%, and 33%, respectively), blood FAA levels (by 35%, 38%, and 46%, respectively), and liver
index (liver weight/body weight) values (by 12.8%, 25%, and 28%, respectively) in the low,
medium, and high EGb761 dose groups, respectively. In further mechanism studies, EGb761 was
found to protect hepatic insulin receptor b and insulin receptor substrate 1 from HFD-induced
degradation, and to keep the AMP-activated protein kinase, which plays a crucial role in reducing
lipotoxicity, from HFD-induced inactivation. We conclude that EGb761 can effectively reduce
HFD-induced insulin resistance and ameliorate other symptoms of the metabolic syndrome.
& 2011 Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical
Association. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Obesity, dyslipidemia, and insulin resistance are major char-
acteristics of a metabolic syndrome. Obesity, especially
abdominal obesity induced by excessive energy intake, con-
tributes to the development of insulin resistance. Obesity and
dyslipidemia are putative risk factors for cardiovascular
diseases (CVD) and type-2 diabetes1. Insulin resistance plays
a central role in the pathogenesis of metabolic syndrome2. It
should be obvious that an early and chronic intervention of
the metabolic syndrome, one that can reduce body weight,
improve insulin sensitivity, and ameliorate dyslipidemia,
represents an important and effective prevention strategy for
overt type-2 diabetes and CVD. Furthermore, given the
potential side effects associated with long-term treatment with
many drugs, natural products with a long history of ther-
apeutic application in humans would be more promising for
this type of chronic intervention.
Ginkgo biloba L. could be one of such natural product
candidates for treating metabolic syndromes. In traditional
Chinese medicine, fruits and seeds of Ginkgo biloba L. have
been used for the treatment of asthma, cough and enuresis3.
EGb761, a standardized extract of Ginkgo biloba leaves, is the
more widely used version of the herbal medicine in the USA
and Europe, largely because of its better quality control,
safety, and tolerability, as compared to other types of Ginkgo
Biloba preparations. As a dietary supplement, EGb761 exerts
multiple therapeutic effects on several diseases; these effects
included improvements in peripheral blood circulation,
increases in cerebral blood perfusion, and prevention of
neurodegenerative disorders, such as Alzheimer’s disease4,5.
Like Ginkgo biloba leaves, EGb761 is also an effective
free radical scavenger6. Its ﬂavonoid fraction exhibits
antioxidant and free radical-scavenging actions7. Recently, it
was reported that EGb761 can protect pancreatic beta
cells against HFD-induced apoptosis in rats8. In addition, it
has been observed that EGb761 could increase insulin secre-
tion from INS-1 cells9. On the basis of the free radical-
scavenging and insulin pro-secretory effects of EGb761, we
hypothesized that EGb761 has therapeutic effects on meta-
bolic syndromes, especially on insulin resistance and asso-
ciated metabolic abnormalities, including obesity and
dyslipidemia.
The aims of present study were to evaluate the effects of
EGb761 on insulin resistance, obesity, and dyslipidemia in theHFD-fed mouse model, and to further explore the underlying
mechanisms. These studies were conducted on C57BL/6 mice,
which developed profound obesity, insulin resistance,
impaired glucose tolerance, and dyslipidemia, when subjected
to a chronic HFD regime10. All those features of the metabolic
syndrome were solely induced by over nutrition under an ad
libitum feeding condition. This obese and insulin resistant
mouse model is ideally suited for studying the pathogenesis of
a diet-induced metabolic syndrome.
2. Materials and methods
2.1. Agents
EGb761 (Batch no. 2K51017) was purchased from Fuwei
Ginkgo Co., Ltd. (Pizhou City, China). It contained 24.40%
total ﬂavone glycosides (10.85% quercetin glycoside, 11.80%
kaempferol glycoside, and 1.75% isorhamnetin glycoside) and
46% total terpenoid lactones (2.8–3.4% lactones A, B, and C;
2.6–3.2% bilobalides); the composition was similar to what was
reported previously4. EGb761 aqueous suspension was pre-
pared freshly, and the preparation was vortex-mixed immedi-
ately before administration. Fenoﬁbrate and Rosiglitazone
were obtained from Laboratoires Fournier S.A (Chenove,
France) and GlaxoSmithKline (USA), respectively. Insulin
(Humulin R) was produced by Lilly (France). All other
reagents were of analytical grade.
2.2. Animals and treatments
Four-week old male C57BL/6J mice were obtained from the
Animal Center of the Institute of Laboratory Animal Sciences,
Chinese Academy of Medical Sciences & Peking Union
Medical College. These mice were housed 4 per cage and
maintained under standardized conditions of temperature
(21–22 1C), humidity (40–60%), and light cycle (between
6 a.m. and 6 p.m. local time). The mice were allowed free
access to either standard laboratory chow (Control) or a HFD
chow, for 18 weeks (from week 4 to week 22 after birth). The
normal chow diet contained (by percentage of total energy)
12% fats, 62% carbohydrates, and 26% proteins, with a total
energy content of 12.6 kJ/g. The HFD contained 60% fat
(mainly from lard), 14% protein, and 26% carbohydrate, with
a total energy content of 21.0 kJ/g. The mice fed HFD were
Wei-na Cong et al.16randomly divided into six groups, including the model group
(Model), the rosiglitazone (an insulin sensitizer)-treated group
(Rosi; at 15 mg/kg body weight/day), the fenoﬁbrate (a lipid-
lowing regent)-treated group (Feno; at 150 mg/kg/day), and
three EGb761-treated groups [EGb(L), EGb(M), and
EGb(H); at 100, 200, and 400 mg/kg/day, respectively]. All
drugs were given once a day by oral gavage in the morning, for
a period of 8 weeks (from week 22 to week 30 after birth). The
Model and the Control group received distilled water by daily
oral gavage as well. Body weights of mice were recorded
weekly.
All mice were sacriﬁced by decapitation, after deprivation
of food for 4 h. The blood samples were collected for assays of
glucose, insulin, lipid proﬁles, and alanine aminotransferase
(ALT) in serum. Livers were removed rapidly, snap frozen in
liquid nitrogen, and stored at 80 1C until use. All animal
experiments were approved by the Beijing Municipal Ethics
Committee for Laboratory Animals.
2.3. Biochemical assays
Serum was obtained at 4 1C, and was analyzed either imme-
diately, or stored at 20 1C until use. Serum triglyceride (TG),
total cholesterol (TC), free fatty acid (FFA), and ALT levels
were determined with spectrophotometric methods with use of
assay kits purchased from Jian Cheng Biotechnology Company
(Nanjing, China). Insulin levels were measured by a radio-
immunoassay kit obtained from the Northern Bioengineering
Institute (Beijing, China).
2.4. Evaluation of insulin sensitivity
Insulin sensitivity was evaluated by the oral glucose tolerance
test (OGTT) and the homeostasis model assessment of insulin
resistance (HOMA-IR) index. Mice were fasted for 4 h before
OGTT. Glucose (2 g/kg body weight) was given by oral
gavage, and blood droplets were collected from the tail at 0,
30, 60, and 120 min after glucose loading. Blood glucose
concentration was immediately determined, with the use of a
glucose analyzer (EKF Diagnostic Company, Germany). The
areas under the glucose concentration–time curve (AUC) were
calculated. The HOMA-IR indices were calculated according
to the following formula, as reported previously11:
HOMA-IR¼ fasting insulin fasting blood glucose=22:5:
2.5. Analysis of hepatic insulin signaling proteins
The expression of insulin signaling proteins was evaluated
using standard Western blot procedures, in total tissue homo-
genate of the liver. Tissues were homogenized in 100 mmol/L
HEPES buffer, pH 7.9, containing 100 mmol/L KCl, 1 mmol/L
DTT, 5% (v/v) glycerol, 5 mmol/L EDTA, 5 mmol/L EGTA,
50 mmol/L phenylmethylsulfonylﬂuoride (PMSF) and 25 ng/
mL leupeptin (Roche). Samples were centrifuged at
12,000 g, at 4 1C, for 60 min, to remove tissue debris, and
the supernatant fraction was kept as a tissue homogenate for
subsequent analysis. Protein concentration was assayed by the
Bradford method, using the Bio-Rad protein assay kit (USA).
Aliquots of the tissue homogenate (containing 30 mg protein)were subjected to electrophoresis on 6% or 10% SDS-poly-
acrylamide gels. Immunoblot analysis was performed using an
enhanced chemiluminescence (ECL) detection system, and
images were acquired using the Fluorchem model-5500 gel
analysis system (Alpha Innotech, USA). The antibodies for
AMP-activated protein kinase (AMPK) (#2532), phosphory-
lated AMP-activated protein kinase (p-AMPK) (#2531), and
insulin receptor (b-subunit) (#3025) were purchased from Cell
Signaling Technology Inc., USA. Antibodies to insulin receptor
substrate 1 (IRS1) (sc-559) and b-actin (sc-1616R) were
obtained from Santa Cruz Biotechnology Inc., USA.
2.6. Statistical analyses
All data are expressed as means7SE. Statistical signiﬁcance of
differences among various groups was analyzed using one-way
ANOVA (SPSS version 10.0, USA). Po0.05 was considered
to be statistically signiﬁcant.
3. Results
3.1. EGb761 diminished HFD-induced obesity, dyslipidemia,
and hepatomegaly
At the end of the 18-week HFD feeding study, body weights of
the Model mice were 68% greater than that of the standard-
chow fed Control mice. After an additional 8 weeks of drug
administration, body weights were noticeably reduced in
EGb(M) and EGb(H) groups, by 11% and 16%, respectively,
as well as in the Feno group (by 22%; as a positive control).
No signiﬁcant body weight change was found in either the
rosiglitazone group or the EGb(L) group (Table 1).
After the HFD feeding, hypercholesterolemia was detected
in the Model mice. Unexpectedly, fasting serum TG and FFA
levels of the Model mice were lower than those of the
Controls. Compared to the levels in the Model group, serum
TC, TG, and FFA levels were signiﬁcantly decreased in both
the fenoﬁbrate group (by 34%, 31%, and 42%, respectively)
and the rosiglitazone group (by 34%, 10%, and 27%,
respectively), as well as in all three of the EGb761 groups
(by 23%, 32%, and 37% for TC, 17%, 23%, and 33% for TG,
and 35%, 38%, and 46% for FFA, in the EGb(L), EGb(M),
and EGb(H) groups, respectively (Table 1).
Hepatomegaly and elevation of ALT levels, which are the
common hepatic features of metabolic syndromes, were also
induced by HFD in our animal model. As a result, liver index
of the Model group was signiﬁcantly higher than that of the
Control group. The HFD-induced increases in liver weight
and serum ALT levels were markedly ameliorated by the
treatments with the three dosages of EGb, in a dose-dependent
manner, as well as by the treatments with rosiglitazone or
fenoﬁbrate. However, values of liver index were signiﬁcantly
decreased only in the Rosi group (by 21%) and in the EGb(M)
and EGb(H) groups (by 25% and 28%, respectively)
(Table 1).
3.2. EGb761 reduced HFD-induced insulin resistance
Hyperinsulinemia is a key hallmark of insulin resistance.
Serum insulin levels were signiﬁcantly boosted in the Model
group (Table 2). Compared to the levels of the Model group,
Table 2 Effects of EGb761 on insulin sensitivity.
Group Insulin (mIU/ml) HOMA-IR
Con 34.075.0 4.970.7
Model 146.0710.1nnn 30.372.6nnn
Rosi 37.475.9### 4.770.7###
Feno 32.874.4### 4.270.5###
EGb(L) 104.0716.3## 15.071.9###
EGb(M) 66.3712.4### 9.471.8###
EGb(H) 44.575.8### 6.071.0###
Value represent means7SE (n¼10).
nnnPo0.001 vs Con.
##Po0.01.
###Po0.001 vs Model.
Table 1 Effects of EGb761 on characteristics of the mice in various treatment groups.
Group Body weight (g) Liver weight (g) Liver index (%) ALT (U/L) TC (mg/dL) TG (mg/dL) FFA (mEq/L)
Con 28.970.6 1.4970.1 4.9170.1 50.573.9 50.778.4 81.3712.3 21717104
Model 48.671.1nnn 3.3470.2nnn 6.7170.4nnn 187711.3nnn 186.4712.3nnn 73.372.2 2041750.3
Rosi 46.972.0 2.5870.2## 5.2870.4# 109719.9### 122.9712.3## 66.375.8 1177746.1###
Feno 38.171.5### 2.7870.2# 7.2770.2 52.876.2### 123.175.7### 50.474.6### 1496776.3###
EGb (L) 46.671.0 2.7470.2# 5.8570.3 112718.9### 144.277.6## 60.973.1## 1332754.9###
EGb (M) 43.271.6### 2.2270.3### 5.0170.4## 97.9718.9### 126.477.4### 56.673.9### 1257746.2###
EGb (H) 40.971.5### 2.0570.2### 4.8270.2### 83.2713.7### 117.677.5### 49.374.9### 1110757.0###
TC, total cholesterol; TG, triglyceride; FFA, free fatty acid. Liver index was calculated as liver weight (g)/body weight (g) 100. Value
represent means7SE (n¼10).
nnnPo0.001 vs Con.
#Po0.05.
##Po0.01.
###Po0.001 vs Model.
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manner, in the EGb(L), EGb(M), and EGb(H) groups (by
29%, 55%, and 70%, respectively). Consistent with the
changes in insulin levels, the Model group had much higher
HOMA-IR index values than the Control group. The HFD-
induced increases in HOMA-IR index values were ameliorated
by the treatments with EGb761 (Po0.001), in a dose-depen-
dent manner (by 50%, 69%, and 80%, in the EGb(L),
EGb(M), and EGb(H) groups, respectively) (Table 2). As
expected treatments with either fenoﬁbrate or rosiglitazone
improved insulin sensitivity by lowering insulin levels and
HOMA-IR values.
Impaired glucose tolerance is another key characteristic of
insulin resistance, especially for hepatic insulin resistance. To
further evaluate the effects of EGb761 on insulin sensitivity,
OGTT was conducted, and AUC values were calculated.
Following HFD feeding, mice in the Model group developed
overt glucose intolerance. Further treatment with EGb761
effectively improved glucose tolerability, decreasing the peak
of blood glucose by 54%, 67%, and 71%, and reducing the
AUC values by 36%, 43%, and 48%, in the EGb(L),
EGb(M), and EGb(H) groups, respectively, compared to the
Model group (Fig. 1). Within our expectations, glucoseintolerance was also markedly diminished by treatments with
fenoﬁbrate or rosiglitazone.3.3. EGb761 protected against HFD-induced inactivation of
hepatic AMPK activity
As an energy sensor, AMPK plays a crucial role in protecting
insulin sensitivity from lipotoxicity. AMPK is activated via
phosphorylation of its a subunit. Thus, the ratio of p-AMPK
to AMPK could reﬂect the activity of AMPK. As shown in
Fig. 2, the activity of AMPK is expected to be reduced in the
Model mice, given the observed decreases in the levels of
p-AMPK. Compared to the expression levels in the Model
group, the expression of p-AMPK (but not AMPK) was
markedly increased in both the rosiglitazone group and the
EGb(H) group. Densitometric analysis (data not shown)
indicated that the ratio of p-AMPK to AMPK was decreased
by 56% in the Model group, compared with that in the
Control group, and it was increased 3, 4, and 2 folds, in the
Rosi, Feno, and EGB(H) groups, respectively, compared with
that in the Model group.3.4. EGb761 blocked HFD-induced loss of insulin receptor
(IRb) and insulin receptor substrate 1 (IRS1) proteins
in the liver
In order to explore the potential mechanisms by which
EGb761 improves insulin sensitivity, we analyzed the expres-
sion of two important proteins of insulin signaling (IRb and
IRS1) in the liver by Western blot. In the Model mice, the
basal expression of IRb was markedly reduced by HFD
feeding. The decrease in IRb expression was markedly
reversed by the treatments with EGb761 (high dosage),
fenoﬁbrate, or rosiglitazone, resulting in increase by 79%,
115%, and 79%, respectively, compared to the levels in the
Model group (Fig. 3). Furthermore, the basal expression levels
of IRS1, a critical downstream factor of insulin receptor, were
also mildly decreased by HFD feeding, and the decrease was
reversed by the treatments with EGb761 or rosiglitazone
(Fig. 3).
Figure 1 Effects of EGb761 on HFD-induced glucose intoler-
ance. Glucose tolerability was assessed by the oral glucose
tolerance test. Diet and treatment groups are described in
Section 2. (a) Blood glucose concentration–time course curves.
(b) Areas under the blood glucose concentration–time course
curves. Values are expressed as means7SE, n¼10. Po0.001
vs Control (Con). ##Po0.01, ###Po0.001 vs Model group. Rosi,
rosiglitazone-treated group; Feno, fenoﬁbrate-treated group;
EGb(L), EGb(M), and EGb(H), EGb761-treated groups, at 100,
200, and 400 mg/kg/day, respectively.
Figure 2 Effects of EGb761 on HFD-induced decreases in
AMPK phosphorylation. AMPK and p-AMPK protein levels
were assessed by Western blot analysis of liver tissue homogenate
preparations from mice of the various dietary and treatment
groups, as in Fig. 1, according to the method described in the text.
Equal amounts of protein (30 mg) were analyzed in each lane.
Wei-na Cong et al.184. Discussion
EGb761 has been used in the treatment of neurodegenerative and
cardiovascular diseases because of its free radical-scavengingproperties and its beneﬁcial effects on blood ﬂow6,12–14. In
addition, EGb761 effectively reduces lipid accumulation and
inhibits formation of atherosclerosis plaques15. EGb761 showed
pro-secretory actions on adiponectin from adipocytes16 and on
insulin from islet b-cells in vitro9. However, the exact relationship
between EGb761 and insulin sensitivity is rarely reported.
Insulin resistance is a key pathogenic factor of type-2
diabetes. Hyperinsulinemia results from a compensation for
insulin resistance, and is detectable until pancreatic secretory
defects occur17. Impaired glucose tolerance, as assessed by
OGTT, indicates insulin resistance and abnormality of glucose
disposal18,19. An elevation of the HOMA-IR index also
demonstrates overt insulin resistance. In our HFD-fed mouse
model, EGb761 effectively reversed hyperinsulinemia, amelio-
rated glucose intolerance, and decreased HOMA-IR values, in
a dose-dependent manner. Taken together, these data strongly
support the conclusion that EGb761 has signiﬁcant therapeu-
tic effects on HFD-induced insulin resistance.
In order to explore the mechanisms for the insulin-sensitizing
effects of EGb761, we analyzed the diet- and drug-induced
changes in the expression of IRb and one of its substrate,
IRS1, in the liver; IRb and IRS1 both play crucial roles in
insulin signaling, and are closely related to lipid homeostasis in
the liver20,21. Selective losses of insulin receptors and their
substrates have been observed in insulin-resistant animal models
in several previous studies20,21. The results of our present study
suggest that EGb761 might enhance hepatic insulin signaling by
protecting IRb and IRS1 proteins against HFD-induced increases
in their degradation. However, further studies are needed to
identify the insulin-stimulated changes in these signaling proteins.
AMPK is a critical node linking insulin signaling and lipid
metabolism, and a positive regulator of insulin resistance22,23.
The down regulation of AMPK activity in HFD-fed mice, as
implicated by decreases in AMPK phosphorylation, reﬂects
potentially negative effects of the changed lipid content on
insulin signaling. The activation of AMPK by EGb761, as
implicated by the increases in AMPK phosphorylation
following EGb761 treatment, would not only improve hepa-
tic lipid metabolism, but also beneﬁt insulin signaling. But,
further research is needed to identify the mechanisms by
which EGb761 modulates AMPK activity, and the conse-
quent effects on insulin signaling.
Besides the insulin-sensitizing effects, EGb761 also signiﬁ-
cantly diminished the HFD-induced obesity and the presence
of high levels of serum total cholesterol and free fatty acids.
These results suggest that the ability of EGb761 to enhance
insulin sensitivity might be partially mediated through ameli-
oration of metabolic dyslipidemia and obesity. Additionally,
as an insulin target organ, the liver plays a key role in lipid and
glucose metabolism. Hepatomegaly, hepatic steatosis, and
elevation of ALT are also regarded as major manifestations
of metabolic syndromes in the liver24,25. Thus, our current
observation, that EGb761 ameliorated hepatomegaly and
decreased ALT levels in a dose-dependent manner, implies
that hepatoprotection by EGb761 might be another mechan-
ism for its insulin-sensitizing action.
In summary, the results of our present study indicate that
EGb761 effectively reversed the HFD-induced insulin resis-
tance and other metabolic symptoms, including obesity,
glucose intolerance, and hepatomegaly. These results provide
new support for the application of EGb761 in the treatment of
type-2 diabetes, especially for insulin resistance. Our
Figure 3 Effects of EGb761 on HFD-induced decreases in the expression of insulin-signaling proteins. (a) IRb and IRS1 protein levels
were assessed by Western blot according to the method described in the text. Equal amounts of protein (30 mg) were analyzed in each
lane. (b) Relative protein expression levels are presented as means7SE, of 10 mice, from three independent experiments. #Po0.05,
##Po0.01 vs Model.
EGb761, an extract of Ginkgo biloba leaves, reduces insulin resistance in a high-fat-fed mouse model 19preliminary mechanistic studies suggest that maintenance of
IR and IRS1 protein levels might be one clue for explaining
the hepatic insulin-sensitizing effects of EGb761. In addition,
preservation of AMPK activity might be another mechanism
by which EGb761 counteracts lipotoxicity and exerts its
insulin-sensitizing action.References
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